Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's quarterly market cap
increased
from Jun. 2025 (¥9,032.4 Mil) to Sep. 2025 (¥9,512.2 Mil) but then
declined
from Sep. 2025 (¥9,512.2 Mil) to Dec. 2025 (¥8,656.9 Mil).
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annual market cap
declined
from Dec. 2023 (¥9,626.9 Mil) to Dec. 2024 (¥7,999.8 Mil) but then
increased
from Dec. 2024 (¥7,999.8 Mil) to Dec. 2025 (¥8,656.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Enterprise Value for Today is ¥5,039.6 Mil.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Market Cap Related Terms
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Market Cap Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Market Cap of ¥6,171.6 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #287 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Market Cap too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Market Cap is ¥6,171.6 Mil. Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #287 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #287 out of 1024 companies for Market Cap. This puts Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the upper half of its industry. The industry median Market Cap is 213.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.52, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Market Cap is ¥6,171.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.46, compared to a current price of ¥7.76 — trading 20.1% above its estimated fair value. The current Market Cap is ¥6,171.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Market Cap is ¥6,171.6 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥7.76 is trading 20.1% above its estimated GF Value™ of ¥6.46.
GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:688505:
Market Cap: ¥6,171.6 Mil
GF Value™: ¥6.46 vs. price of ¥7.76 (20.1% above fair value)
No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
67GF Score
Get the complete analysis for SHSE:688505
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688505 has been successfully added to your 
